FY2018 EPS Estimates for Astrazeneca PLC (AZN) Increased by Analyst
Astrazeneca PLC (NYSE:AZN) – Equities researchers at Jefferies Group boosted their FY2018 earnings per share estimates for Astrazeneca PLC in a research note issued on Monday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings of $1.95 per share for the year, up from their prior forecast of $1.91. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2019 earnings at $2.05 EPS, FY2020 earnings at $2.36 EPS and FY2021 earnings at $2.77 EPS.
Other analysts have also recently issued reports about the stock. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Argus restated a “buy” rating and issued a $35.00 price target on shares of Astrazeneca PLC in a report on Friday, September 1st. Natixis upgraded shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Finally, Morgan Stanley cut shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Astrazeneca PLC currently has an average rating of “Hold” and a consensus price target of $33.60.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 2.39% on Wednesday, reaching $32.62. 4,722,635 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $30.16 and a 200-day moving average price of $31.70. The company has a market cap of $82.59 billion, a PE ratio of 21.40 and a beta of 0.74. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s revenue for the quarter was down 9.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.83 earnings per share.
The firm also recently declared a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were given a dividend of $0.44 per share. This represents a yield of 2.98%. The ex-dividend date was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio is presently 44.92%.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Intl Fcstone Inc. raised its position in Astrazeneca PLC by 146.9% during the 2nd quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after buying an additional 19,365 shares during the last quarter. WFG Advisors LP raised its position in Astrazeneca PLC by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after buying an additional 984 shares during the last quarter. Rikoon Group LLC raised its position in Astrazeneca PLC by 1.3% during the 2nd quarter. Rikoon Group LLC now owns 35,780 shares of the company’s stock worth $1,219,000 after buying an additional 450 shares during the last quarter. BB&T Investment Services Inc. purchased a new position in Astrazeneca PLC during the 2nd quarter worth approximately $512,000. Finally, Raymond James Financial Services Advisors Inc. raised its position in Astrazeneca PLC by 18.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 96,442 shares of the company’s stock worth $3,288,000 after buying an additional 15,098 shares during the last quarter. 14.18% of the stock is owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.